Enliven Therapeutics' stock experienced a sharp intraday advance of nearly 19.9% in morning trading after the clinical-stage biopharmaceutical firm disclosed updated Phase 1 findings for its lead chronic myeloid leukemia candidate, ELVN-001. The new data were presented at the European Hematology Association 2026 Congress in Stockholm and derive from the ENABLE trial.
The dataset reflected 161 enrolled patients as of a March 10, 2026 cutoff and highlighted outcomes in the 80 mg once-daily Phase 1b cohort. In that cohort the company reported an overall major molecular response rate of 61%, with 76% of patients remaining on study at a median treatment duration of 35 weeks. Market participants interpreted these results as supporting the prospect that ELVN-001 may have best-in-class potential within its therapeutic niche.
Equally consequential for investors was Enliven's announcement that the U.S. Food and Drug Administration has agreed with the company on 80 mg once daily as the recommended dose for the planned Phase 3 program. The company said the pivotal ENABLE-2 trial is expected to begin enrolling patients in the second half of 2026, establishing a clear regulatory and development pathway for the program.
Analyst activity ahead of and surrounding the data release added momentum to the share move. Guggenheim initiated coverage with a Buy rating and an $80 price target, stating that ELVN-001's profile is not yet fully reflected in Enliven's market value. Stifel also began coverage with a Buy rating and a $60 target, while Mizuho raised its target to $62 from $45 and kept an Outperform rating. Those broker actions contributed to a growing bullish consensus that had been forming in the weeks leading up to the presentation.
Enliven's financial position provided an additional supportive backdrop. The company entered the quarter with approximately $452.4 million in cash and short-term investments and reported zero debt. That liquidity position was cited as sufficient to fund the program through key near-term milestones without the immediate need for dilutive financing.
Market context underscored that ELVN's move was largely idiosyncratic. Broad U.S. equity indices were modestly higher on the day, with the S&P 500 up 0.3%, the Dow Jones Industrial Average up 0.5%, and the Nasdaq up 0.3%. Peer biotech names posted mixed returns, indicating that the rally in Enliven shares was driven principally by company-specific developments rather than a sector-wide surge.
Taking these factors together - encouraging Phase 1 efficacy and safety readouts, FDA alignment on the Phase 3 dose, ample cash resources and an accumulation of bullish analyst coverage - the stock reached a session high of $45.52, closing in on its 52-week high of $48.53. Investors and analysts will likely focus on the upcoming milestones tied to the ENABLE-2 enrollment timeline and subsequent pivotal readouts.
Summary
Enliven Therapeutics rose sharply after reporting updated Phase 1 results for ELVN-001 showing a 61% overall major molecular response in the 80 mg once-daily cohort. The FDA has agreed with the company on the 80 mg once-daily Phase 3 dose, and the ENABLE-2 pivotal trial is expected to start enrolling in the second half of 2026. Analyst initiations and upgrades and a cash balance of about $452.4 million with no debt reinforced the market reaction.